Citigroup Maintains Buy on Guardant Health, Raises Price Target to $215

Benzinga · 07/08 16:05
Citigroup analyst Patrick Donnelly maintains Guardant Health (NASDAQ:GH) with a Buy and raises the price target from $150 to $215.